Elexacaftor / tezacaftor / ivacaftor · Trikafta

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Cystic Fibrosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (1)
EU
  • Cystic fibrosis (with ivacaftor), at least one non-Class I CFTR mutation; sold in the EU as Kaftrio
Product first approved 2020EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (21)
Cystic Fibrosis
NCT06460506 · Vertex Pharmaceuticals Incorporated
2024-11-21 – 2027-09-30 · Cystic Fibrosis
What this study did
NCT05331183 · Vertex Pharmaceuticals Incorporated
2022-11-23 – 2027-04-06 · Cystic Fibrosis
What this study did
NCT05153317 · Vertex Pharmaceuticals Incorporated
2022-01-17 – 2026-01-29 · Cystic Fibrosis
What this study did
NCT05882357 · Vertex Pharmaceuticals Incorporated
2023-06-27 – 2025-09-04 · Cystic Fibrosis
What this study did
NCT04183790 · Vertex Pharmaceuticals Incorporated
2020-02-17 – 2024-02-24 · Cystic Fibrosis
What this study did
NCT04545515 · Vertex Pharmaceuticals Incorporated
2021-01-11 – 2023-03-24 · Cystic Fibrosis
What this study did
NCT03525574 · Vertex Pharmaceuticals Incorporated
2018-10-09 – 2023-01-09 · Cystic Fibrosis
What this study did
NCT04362761 · Vertex Pharmaceuticals Incorporated
2020-05-04 – 2022-12-21 · Cystic Fibrosis
What this study did
NCT05111145 · Vertex Pharmaceuticals Incorporated
2022-01-14 – 2022-12-20 · Cystic Fibrosis
What this study did
NCT04058366 · Vertex Pharmaceuticals Incorporated
2019-12-05 – 2022-12-16 · Cystic Fibrosis
What this study did
NCT04043806 · Vertex Pharmaceuticals Incorporated
2019-08-09 – 2022-12-14 · Cystic Fibrosis
What this study did
NCT04969224 · Vertex Pharmaceuticals Incorporated
2021-10-12 – 2022-07-26 · Cystic Fibrosis
What this study did
NCT04599465 · Vertex Pharmaceuticals Incorporated
2021-01-15 – 2022-07-14 · Cystic Fibrosis
What this study did
NCT04537793 · Vertex Pharmaceuticals Incorporated
2020-11-19 – 2022-06-03 · Cystic Fibrosis
What this study did
NCT04353817 · Vertex Pharmaceuticals Incorporated
2020-06-19 – 2021-05-17 · Cystic Fibrosis
What this study did
NCT03691779 · Vertex Pharmaceuticals Incorporated
2018-10-02 – 2020-08-07 · Cystic Fibrosis
What this study did
NCT04105972 · Vertex Pharmaceuticals Incorporated
2019-10-03 – 2020-07-24 · Cystic Fibrosis
What this study did
NCT04058353 · Vertex Pharmaceuticals Incorporated
2019-08-28 – 2020-06-12 · Cystic Fibrosis
What this study did
Phase 2 (1)
Cystic Fibrosis
NCT03506061 · Emory University
2019-09-04 – 2024-02-13 · Cystic Fibrosis
What this study did
Phase 1 (1)
Cystic Fibrosis
NCT07283770 · Vertex Pharmaceuticals Incorporated
2025-12-09 – 2027-07-12 · Cystic Fibrosis
What this study did
Phase 4 (3)
Cystic Fibrosis
NCT04602468 · Royal College of Surgeons, Ireland
2020-09-03 – 2029-07-01 · Cystic Fibrosis, Cystic Fibrosis Liver Disease, Cystic Fibrosis in Children, Adherence, Medication, Cystic Fibrosis Gastrointestinal Disease
What this study did
Other / comorbidity
NCT05743946 · Emory University
2023-04-18 – 2025-12-23 · Non-cystic Fibrosis Bronchiectasis
What this study did
NCT04840862 · University of Southern California
2022-05-09 – 2024-05-30 · Drug Drug Interaction
What this study did
Early phase / not applicable (1)
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Cystic Fibrosis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Elexacaftor / Tezacaftor / Ivacaftor (Trikafta): this drugApprovedSmall moleculeCFTRReliable signal
NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results).
NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results).
Ivacaftor (Kalydeco)ApprovedSmall moleculeCFTRPartial signal
NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1)
NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7)
Lumacaftor (Orkambi)ApprovedSmall moleculeCFTRReliable signalNo reviewed efficacy summary in this indication
Tezacaftor / Ivacaftor (Symdeko)ApprovedSmall moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek)ApprovedSmall moleculeCFTR, CFTRReliable signalNo reviewed efficacy summary in this indication
KB407Phase 1Gene therapy / editingCFTR (gene replacement)not yet gradedNo reviewed efficacy summary in this indication
VX-828Phase 1Small moleculeCFTRnot yet gradedNo reviewed efficacy summary in this indication
LuvomeranDiscontinuedRNA / oligonucleotideCFTR (mRNA replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trikafta (Elexacaftor / tezacaftor / ivacaftor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
April 2027 (1)
Phase 3Cystic FibrosisActive not recruiting
Est. primary completion 2027-04-06 · NCT05331183 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Cystic FibrosisRecruiting
Est. primary completion 2027-07-12 · NCT07283770 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Cystic FibrosisActive not recruiting
Est. primary completion 2027-09-30 · NCT06460506 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Phase 4Cystic FibrosisActive not recruiting
Est. primary completion 2029-07-01 · NCT04602468 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

June 2026Filing submittedVertex begins global regulatory submissions for TRIKAFTA in children aged 1 to under 2 years
Vertex Pharmaceuticals Incorporated · Source ↗